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e.2011.12Abstract Background: Serum levels of gastrin-17 (S-G-17) and pepsinogen I (S-PGI) are biomark-
ers of gastric antral and corpus mucosa, respectively. We determined whether these tests, together
with the assay of Helicobacter pylori antibodies, are a nonendoscopic tool for the diagnosis of
atrophic gastritis.
Objectives: To study the relation between H. pylori infection and atrophic gastritis in the elderly
through the estimation of gastrin 17 and pepsinogen I as novel noninvasive diagnostic biomarkers.
Material and methods: The present study included sixty individuals suffering from gastritis there
were divided into two groups. Group (I): Thirty patients having H. pylori infection aged above
65 years. Group (II): Thirty patients without H. pylori infection aged above 65 years. All individu-
alswere subjected to diagnostic upper-gastrointestinal endoscopy and speciﬁc gastric biomarkers
(serum gastrin-17, serum pepsinogen I/II).ori; PGI, Pepsinogen I; PGII,
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290 S.I. Gomaa et al.Results: Serum pepsinogen I, II, ratio and gastrin 17 decrease with increasing grade of atrophy of
the antrum respectively. Serum pepsinogen I, II, gastrin 17 were signiﬁcantly lower in mild, mod-
erate, and severe gastritis compared to superﬁcial gastritis patients.
Conclusion: The diagnosis of atrophic gastritis obtained with the blood test panel of G.17, SPG I/II
andH. pylori antibodies is in good agreement with the endoscopic and biopsy ﬁnding. The panel is a
tool for nonendoscopic diagnosis and screening of atrophic gastritis.
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reserved.1. Introduction
Aging is a basic natural and biological process that goes on
continuously in every individual and is responsible for changes
affecting the organs by the passage of time. It starts with the
onset of life and is terminated by death.1
H. pylori infection increases with age. Its prevalence was
found to approach 75% in patients above 65 years of age.2–4
A recent retrospective study has found that H. pylori infec-
tion is associated with the majority of cases of symptomatic
gastritis in the elderly patients.5
Recent studies have demonstrated a clear association be-
tween gastric colonization with H. pylori, gastritis and peptic
ulcer disease.6,7 Other epidemiological studies have also shown
an association between infections with H. pylori and gastric
cancer, the evidence is so complete that the world health orga-
nization has recently categorized H. pylori as a category I car-
cinogen.8–12
Gastric atrophy characterized by the loss of antrum glands
is considered a precursor of gastric adenocarcinoma since H.
pylori increases the risk of gastric adenocarcinoma. It was been
classiﬁed as a class I oncogenic factor,13 despite the central role
of atrophic gastritis as a major risk factor for gastric carci-
noma. Its diagnosis and its grading and proper assessments
are done poorly or not at all in clinical practice.14
Because H. pylori infection is a necessary causative factor in
the majority of cases of gastric cancer, eradication of the infec-
tion will very likely reduce the incidence of gastric cancer.14
The assays of serum/plasma pepsinogen I, pepsinogen II
and pepsinogen I/pepsinogen II ratio in addition to gastrin
17 are easy tools for assessment of the presence or absence
of atrophic gastritis even in a clinical setting whereas endos-
copy is not available.
1.1. The aim of this work
To study the relation between H. pylori infection and atrophic
gastritis in the elderly through the estimation of serum (gas-
trin-17 and pepsinogen-I) as novel noninvasive diagnostic
biomarkers.
2. Methods
The present study included 60 individuals suffering from gas-
tritis divided into two groups.
Group (I): Thirty patients having H. pylori infection aged
above 65 years.
Group (II): Thirty patients without H. pylori infection aged
above 65 years.
All patients included in the study were recruited from Main
University Hospital and Fever Hospital.2.1. Exclusion criteria
Patients with any other disease causing gastric insult were ex-
cluded from the study as were patients with diabetes mellitus,
autoimmune diseases, chronic systemic infection, liver disease,
chronic renal diseases and neoplastic disorders and also pa-
tients receiving drugs known to affect the gastric mucosa.
After taking a written consent from all patients, they were
subjected to:
2.2. Endoscopy and biopsy sampling
Diagnostic upper gastrointestinal endoscopy was performed in
all patients, two biopsies were taken from antrum to detect H.
pylori, one for rapid urease and the other one for histopathol-
ogical examination.
The biopsy specimens were immediately placed in a ﬁxative
(10% buffered formalin). The formalin ﬁxed specimens rou-
tinely processed and embedded in parafﬁn blocks were serially
cut and mounted on glass slides. The slides were stained with
the conventional H&E stain. The prepared section was care-
fully examined by the light microscope and scored semi-quan-
titatively according to the updated Sydney classiﬁcation
system.15
2.3. Blood samples
The basal blood samples for the measurement of PGI, PGII,
and gastrin 17 were obtained with the subjects in recumbent
position, after an overnight fast, after venipuncture, serum
and plasma sample were centrifuged and therefore kept at
room temperature for 2 h. Before analysis samples were frozen
at 20 C for the latter assay of gastrin and pepsinogen.
Diagnosis of atrophic gastritis by the blood test panel in
delineation of patients with different topographic types of
atrophic gastritis took place ;with the blood test panel an algo-
rithm and a computer program (Gastrosuft, Bioint Plc) were
used.
Three criteria for the best discrimination of gastritis of dif-
ferent types were obtained from previous studies.15,16
2.4. Laboratory tests
2.4.1. Gastropanel test
(a) Estimation of H. pylori IgG by ELISA with references
negative <30, positive >30.17
(b) Estimation of pepsinogen I by ELISA with reference
range of 30–105 lg/l.17
(c) Estimation of gastrin 17 by ELISA with a reference
range of 1–10 mmol.17
Table 1 Demographic data in the studied groups.
H. pylori n Min Max Mean SD t P
Age (years) Negative 30 62 81 69.4 5.04 0.585 0.561
Positive 30 65 78 70.1 3.69
BMI (kg/m2) Negative 30 17 24 21.2 2.20 0.483 0.631
Positive 30 17 24 20.9 2.07
*P is signiﬁcant if <0.05.
Table 2 Relation between degree of gastritis and the other parameters.
Gastritis degree n Mean SD F P LSD
Pepsinogen 1 Superﬁcial 27 122.4 41.75 56.052 0.000* Superﬁcial vs others Mild vs moderate and severe
Mild 9 66.0 22.36
Moderate 11 19.6 4.34
Severe 13 9.6 5.31
Pepsinogen 2 Superﬁcial 27 52.3 27.31 10.399 0.000* Superﬁcial and mild vs moderate and severe
Mild 9 40.8 28.90
Moderate 11 18.5 17.03
Severe 13 13.3 14.23
Pepsinogen 1/2 ratio Superﬁcial 27 3.7 3.85 3.606 0.041* Superﬁcial and mild vs moderate and severe
Mild 9 3.2 3.23
Moderate 11 1.8 1.01
Severe 13 1.2 1.06
Gastrin Superﬁcial 27 31.4 25.29 3.169 0.031* Superﬁcial and mild vs moderate and severe
Mild 9 31.3 20.07
Moderate 11 15.8 11.19
Severe 13 15.3 5.22
H. pylori antibody Superﬁcial 27 16.6 4.09 37.575 0.000* Superﬁcial vs others
Mild 9 34.5 13.85
Moderate 11 37.4 4.84
Severe 13 41.4 10.60
* P is signiﬁcant if <0.05.
Table 3 Relation between H. pylori and degree of gastritis.
H. pylori X2 P
Negative Positive
Superﬁcial 27
90.0%
Mild 3 6
10.0% 20.0%
Moderate 11 57.00 0.000*
36.7%
Severe 13
43.3%
30 30
* P is signiﬁcant if <0.05.
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ence range of 4–9 ng/ml.17
(e) Estimation of pepsinogen I/II ratio by ELISA with ref-
erence range of 3–20.
2.5. Statistical methods
The Data were collected and entered into the personal com-
puter. Statistical analysis was done using Statistical Package
for Social Sciences (SPSS/version 17) software.Arithmetic mean, standard deviation, for categorized
parameters, chi-square test was used while for numerical data
t-test was used to compare two groups while for more than two
groups ANOVA test was used, least signiﬁcant differences
(LSD) was basically a t-test used only when the F-value is sig-
niﬁcant to detect the presence of signiﬁcance between each of
the two groups. The level of signiﬁcance was 0.05.
3. Results
The mean age was 69.4 ± 5.04 years in H. pylori +ve group
and 70.1 ± 3.69 years in H. pylori ve group. There was no
signiﬁcant difference between both groups (P is signiﬁcant if
<0.05) (Table 1).
The mean body mass index (BMI) was 21.2 ± 2.20 kg/m2
in H. pylori +ve group and 20.9 ± 2.07 kg/m2 in H. pylori
ve group. There was no signiﬁcant difference between both
groups. (P is signiﬁcant if <0.05) (Table 1).
The mean serum pepsinogen I was signiﬁcantly lower in
H. pylori+ve group (23.9 ± 21.84) unit compared toH. pylori
ve group (117.4 ± 43.47). (P is signiﬁcant if <0.05) (Table
2).
The mean serum pepsinogen II was signiﬁcantly lower in
H. pylori +ve group (23 ± 23.31) unit compared to H. pylori
ve group (48.1 ± 28.94). (P is signiﬁcant if <0.05) (Table 2).
The mean serum pepsinogen I/II ratio was signiﬁcantly
lower in H. pylori +ve group (1.4 ± 0.98) unit compared to
Figure 1 Relation between degree of gastritis and pepsinogen I
and II.
Figure 2 Relation between degree of gastritis and pepsinogen I/
II ratio.
Figure 3 Relation between degree of gastritis and serum gastrin.
Figure 4 Relation between degree of gastritis and H. pylori
antibody.
292 S.I. Gomaa et al.H. pylori ve group (4.1 ± 3.85). (P is signiﬁcant if <0.05)
(Table 2).
The mean serum gastrin was signiﬁcantly lower in H. pylori
+ve group (32.8 ± 25.92) compared to H. pylori ve group
(17.3 ± 8.24). (P is signiﬁcant if <0.05) (Table 2).
The mean serum pepsinogen I was signiﬁcantly lower in
mild, moderate and severe gastritis patients compared to
superﬁcial gastritis patients and it was signiﬁcantly lower in
moderate and severe gastritis patients compared to mild gastri-
tis patients. (P is signiﬁcant if <0.05) (Table 3, Fig. 1).
The mean serum pepsinogen II was signiﬁcantly lower in
moderate and severe gastritis compared to superﬁcial and mild
gastritis patients. The mean serum pepsinogen I/II ratio was
signiﬁcantly lower in moderate and severe gastritis patients
compared to superﬁcial and mild gastritis patients. (P is signif-
icant if <0.05) (Table 3, Figs. 1 and 2).The mean serum gastrin was signiﬁcantly lower in moderate
and severe gastritis patients compared to superﬁcial and mild
gastritis patients. (P is signiﬁcant if <0.05) (Table 3, Fig. 3).
The mean H. pylori antibody was signiﬁcantly higher in
mild, moderate and severe gastritis patients compared to
superﬁcial gastritis patients (Fig. 4).
As regards serum pepsinogen I at cut off value <97, sensi-
tivity was 100%, speciﬁcity 81.5%, positive predictive value
86.81, negative predictive value 100% and accuracy 91.7% in
detecting atrophic gastritis (Table 4).
As regards serum pepsinogen II at cut off value <52 sensi-
tivity was 93.9%, speciﬁcity 63% positive predictive value
75.6%, negative predictive value 89.5% and accuracy 80% in
detecting atrophic gastritis (Table 4).
As regards serum pepsinogen I/II ratio at cut off value
<1.82 sensitivity was 66.7% speciﬁcity 66.7%, positive predic-
tive value 71.0% negative predictive value 62.1% and accuracy
66.7% in detecting atrophic gastritis (Table 4).
As regards serum gastrin at cut off value <28 sensitivity
was 90.9%m speciﬁcity 44.4% positive predictive value
66.7%, negative predictive value 80%, accuracy 70% in detect-
ing atrophic gastritis (Table 4).
4. Discussion
The present study indicates that, in association with H. pylori
testing, the serum level of G-17 and PGI can be used as bio-
markers of gastritis and atrophic gastritis in the antrum. In
the present study S.G.17 decreased with increasing grade of
antral atrophy among H. pylori infected patient. Correspond-
ingly S-PGI decreased with increasing grade of antral atrophy
in a way that has been demonstrated in many previous studies.
18–24
Studies by using all three blood tests (H. pylori antibody as-
say, SG17, and SPGI as panels were done and by using the
gastro soft computer program to generate the diagnosis it
was possible to delineate the patients with advanced atrophic
gastritis with a reasonably high accuracy. The data from the
present prospective study among gastritis patients were com-
parable with those from observational case, control study25
and prospective Italian study,26 these three studies suggested
that the overall accuracy of the panel in the diagnosis of
atrophic gastritis is approximately 80% when compared with
the diagnosis from endoscopy and biopsies.
Serum PG known to be a marker for gastritis serum PG has
been reported to be a marker for atrophic gastritis27,28 and is
Table 4 Evaluation of different markers in prediction of atrophic gastritis.
Cut oﬀ value Sensitivity Speciﬁcity Positive predictive value Negative predictive value Accuracy
Serum pepsinogen 1 <97 100.0 81.5 86.8 100.0 91.7
Serum pepsinogen 2 <52 93.9 63.0 75.6 89.5 80.0
Serum pepsinogen 1/2 ratio <1.82 66.7 66.7 71.0 62.1 66.7
Serum gastrin <28 90.9 44.4 66.7 80.0 70.0
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concentration deﬁnes groups at high risk of gastric cancer
and adenoma32,33 in describing the relationship between gastri-
tis and pepsinogen concentrations, Samloff et al.27 used the
term ‘‘serologic biopsy’’ and Miki et al.28 reported that I:II ra-
tio was correlated with the extent of atrophic gastritis.
Diagnosis of atrophic gastritis by biopsy specimen is often
unreliable and the interobserver variation is large in particular
in antral biopsy. This may be due to the fact that atrophic le-
sions are often patchy due to the fact that atrophic lesions are
often patchy and a limited number of biopsy specimens may
easily result in under or over diagnosis, the existing inﬂamma-
tion may also bias the microscopic appearance that leads to
over estimation of atrophic gastritis due to artiﬁcial impression
of loss of glands. It is conceivable that the blood test panel
avoids these biases.34
Therefore the blood test panel is not a direct test for cancer
or peptic ulcer but it may reveal patients who are at risk for
this disease and when endoscopy is mandatory.34
5. Conclusion
From the study we concluded that H. pylori is common in the
elderly and it is the most important cause of atrophic gastritis
in the elderly. Atrophic gastritis in the elderly is considered as a
major risk factor for gastric carcinoma. The diagnosis of
atrophic gastritis obtained with the blood test panel of SG17
SPGI, ratio and H. pylori antibodies is in good agreement with
the endoscopic and biopsy ﬁndings.
Our study recommends that the blood test panel is a nonin-
vasive alternative in the initial examination of patient dyspep-
sia. The panel helps to identify easily and nonendoscopically
patients with atrophic gastritis in the antrum.
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